(Exlinkibart)Biosimilar Reference Antibody-GS40255

货号：GS40255

Exlinkibart (development code LVGN-6051) is an investigational humanized immunoglobulin G1 kappa (IgG1κ) monoclonal antibody being developed for the treatment of advanced solid malignancies, including lung cancer and melanoma. The humanization was achieved using complementarity-determining region (CDR) grafting technology, where the antigen-binding loops (CDRs) from a non-human antibody are transplanted onto a human IgG1κ framework to minimize immunogenicity while retaining target affinity. Exlinkibart functions as a targeted agonist of TNFRSF9 (4-1BB/CD137). By binding to and activating the 4-1BB receptor, it delivers a potent co-stimulatory signal to immune cells, enhancing T-cell and natural killer (NK) cell proliferation, survival, cytokine production, and cytotoxic function, thereby amplifying the anti-tumor immune response.